Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 26, Issue 4, 2010, Pages 407-417

  Ross, Lisa L ^a   Weinberg, Winkler G ^b   Dejesus, Edwin ^c   Fischl, Margaret A ^d   Horton, Joseph H ^a   Pappa, Keith A ^a   Lancaster, C Tracey ^a   Pakes, Gary E ^a   Smith, Kimberly Y ^e  

^a GLAXOSMITHKLINE   (United States)

^b KAISER PERMANENTE   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; CLONAL VARIATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PHOSPHORIC ACID ESTERS; PYRIDINES; RITONAVIR; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SULFONAMIDES; TREATMENT FAILURE;

EID: 77951848730     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0189     Document Type: Article

References (20)

1. Hogg RS, Bangsberg DR, Lima VD, et al.: Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3: 1570-1577.
2. Simen BB, Simons JF, Hullsiek KH, et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009;199:693-701.
3. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008;5:1112-1121.
4. Hammer SM, Eron JJ, Jr., Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
5. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47:266-285.
6. Toni TA, Asahchop EL, Moisi D, et al.: Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 2009;53:1670-1672.
7. Smith KY, Weinberg WG, DeJesus E, et al.: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
9. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.
10. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.
11. Kumar S, Nei M, Dudley J, and Tamura K: MEGA: A biologist- centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 2008;9:299-306.
12. Ross LL, Wine BC, Vavro C, et al.: Changes in regional prevalence, clade and epidemiology of HIV-1 drug resistance mutations and clade among antiviral therapy-naive patients in the United States (US) from 2000 to 2007. Antiviral Ther 2008;13(S3):A160.
13. Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008, 1-139. Available at http:// www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescent GL.pdf. Accessed July 25, 2009.
14. European AIDS Clinical Society (EACS): Guidelines for the clinical management and treatment of HIV infected adults in Europe. Oct 1, 2008. Available at http://www. europeanaidsclinicalsociety.org/guidelines.asp. Accessed July 25, 2009.
15. Molina JM, Andrade-Villanueva J, Echevarria J, et al.: Oncedaily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1- infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655.
16. Elion R, Cohen C, Ward D, et al.: Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials 2008;9(4):213-224.
17. Elion R, DeJesus E, Sension M, et al.: Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: A 48-week pilot study. HIV Clin Trials 2008;9(3):152-163.
18. Hicks CB, DeJesus E, Sloan LM, et al.: Comparison of oncedaily fosamprenavir boosted with either 100 or 200mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses 2009;25:395-403.
19. Deeks SG: Transmitted minority drug-resistant HIV variants: A new epidemic? PLoS Med 2008;5:e164.
20. Lataillade M, Chiarella J, Yang R, et al.: Prevalence and clinical significance of transmitted drug-resistant (TDR) HIV mutations by ultra deep sequencing (UDS) in HIV-infected ARV-naïve subjects in CASTLE Study. Antiviral Ther 2009;14(S1):A44.